<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04481412</url>
  </required_header>
  <id_info>
    <org_study_id>Cetirizine in alopecia</org_study_id>
    <nct_id>NCT04481412</nct_id>
  </id_info>
  <brief_title>Topical Cetirizine in Androgenetic Alopecia in Females</brief_title>
  <official_title>The Role of Cetirizine in Androgenetic Alopecia in Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist,&#xD;
      widely used in daily practice. A study showed that cetirizine causes a significant reduction&#xD;
      in both the inflammatory cell infiltrate and PGD2 production. A pilot study on topical&#xD;
      cetirizine showed that cetirizine increased total hair density, terminal hair density and&#xD;
      diameter. Also, its lower potential side effects if compared with other drugs commonly used&#xD;
      for AGA, as minoxidil, can promote a wider use and better compliance of cetirizine in the&#xD;
      future for the treatment of AGA. Combinations of therapies are likely to be more efficacious&#xD;
      than single treatments.&#xD;
&#xD;
      Treatments to clinically improve scalp hair density and reduce mid-pattern thinning leading&#xD;
      to improved scalp coverage are highly important for the affected women. On the basis of the&#xD;
      above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA&#xD;
      treatment, the aim of this study is to evaluate the efficacy and tolerability of topical&#xD;
      cetirizine in female patients with AGA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Androgenetic alopecia (AGA) is the most common form of alopecia in men and women. It is a&#xD;
      hereditary, androgen-dependent, progressive thinning of scalp hair that follows a defined&#xD;
      pattern. The disease mechanism is still relatively poorly understood, but involves a strong&#xD;
      genetic contribution as well as some environmental input. AGA manifests as a noticeable&#xD;
      reduction of scalp hair coverage, shorter miniaturized telogen vellus hair follicles, and&#xD;
      significantly slower rates of hair growth. Approximately 6% to 38% of healthy women&#xD;
      experience some degree of frontal and frontoparietal hair loss. AGA may have significant&#xD;
      impact on quality of life in female patients. When female AGA is associated with high levels&#xD;
      of androgens, systemic antiandrogenic therapy may be needed. However, treating it with oral&#xD;
      antiandrogens is usually ineffective suggesting that most female AGA cases are not systemic&#xD;
      androgen dependent and topical treatment may be more appropriate.&#xD;
&#xD;
      Currently, the only clinically validated and licensed medication approved for increasing hair&#xD;
      density in women with AGA is 2 % minoxidil topical solution, and up to 5% minoxidil in&#xD;
      several countries. The collective effects of minoxidil lead to increased cutaneous blood&#xD;
      flow, prolongation of the anagen growth phase, and increase in the size of smaller hair&#xD;
      follicles. However, it produces moderate results, and must continue to be used to have a&#xD;
      continued benefit, and may produce adverse side effects. The use of higher concentrations of&#xD;
      minoxidil in women is supported by results from an early study suggesting that concentrations&#xD;
      higher than 2% could improve efficacy without increasing the rates of adverse events when&#xD;
      applying not more than 60 mg of minoxidil per day.&#xD;
&#xD;
      Based on the hypertrichosis observed in patients treated with analogues of prostaglandin F2a&#xD;
      (PGF2a) (i.e. latanoprost used for glaucoma), it was supposed that prostaglandins would have&#xD;
      an important role in hair growth. Their action is variable depending on the class they belong&#xD;
      to: prostaglandin E(PGE) and PGF2a play a generally positive role on the hair growth, while&#xD;
      PGD2 has an inhibitory role on the hair growth. Elevated levels of prostaglandin D2 synthase&#xD;
      (PGDS) were found at the messenger ribonucleic acid (mRNA) and protein levels in bald scalp&#xD;
      versus haired scalp of men with AGA; as well as the enzymatic product of PGDS, (PGD2), is&#xD;
      generally elevated in bald human scalp tissue.&#xD;
&#xD;
      Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist,&#xD;
      widely used in daily practice. A study showed that cetirizine causes a significant reduction&#xD;
      in both the inflammatory cell infiltrate and PGD2 production. However, these effects&#xD;
      apparently are not related to its anti-H1 activity. A pilot study on topical cetirizine&#xD;
      showed that cetirizine increased total hair density, terminal hair density and diameter.&#xD;
      Also, its lower potential side effects if compared with other drugs commonly used for AGA, as&#xD;
      minoxidil (which often cause of hypertrichosis, contact allergic dermatitis, headache and&#xD;
      hypotension), can promote a wider use and better compliance of cetirizine in the future for&#xD;
      the treatment of AGA. Combinations of therapies are likely to be more efficacious than single&#xD;
      treatments.&#xD;
&#xD;
      Treatments to clinically improve scalp hair density and reduce mid-pattern thinning leading&#xD;
      to improved scalp coverage are highly important for the affected women. On the basis of the&#xD;
      above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA&#xD;
      treatment, the aim of this study is to evaluate the efficacy and tolerability of topical&#xD;
      cetirizine in female patients with AGA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2020</start_date>
  <completion_date type="Actual">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in number of terminal hairs and vellus hair</measure>
    <time_frame>baseline, 12, 24 weeks</time_frame>
    <description>Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in number of terminal hairs, growing hair and vellus hair.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in hair shaft thickness</measure>
    <time_frame>baseline, 12, 24 weeks</time_frame>
    <description>Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in hair shaft thickness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in terminal and vellus hair density</measure>
    <time_frame>baseline, 12, 24 weeks</time_frame>
    <description>Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in number of follicular openings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in patient self-assessment from baseline</measure>
    <time_frame>baseline, 6, 12, 18, 24 weeks</time_frame>
    <description>Patient self-assessment of hair growth will be determined by means of a set of predetermined 5 questions in Arabic, each of which asks the patient about a specific aspect of their hair compared with the start of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in hair growth from baseline using global photographic assessment</measure>
    <time_frame>baseline, 12, 24 weeks</time_frame>
    <description>Standardized photographs of the scalp will be taken.&#xD;
An expert panel of 3 blinded dermatologists will evaluate hair growth or loss from baseline by comparing baseline with follow-up photographs of each subject by means of a 7-point scale to answer the following question: &quot;How would you subjectively rate the patient's hair growth at this time point compared to baseline?&quot;. The scale ranges from-3 ( greatly decreased) to +3 (greatly increased). Assessments will be made at the 12th and 24th week by comparing the global photographs taken at baseline with those taken at each visit.&#xD;
Investigator assessment: Same as the expert panel assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse effects</measure>
    <time_frame>6, 12, 18, 24 weeks</time_frame>
    <description>Reports of adverse effects or local intolerance, if any, will be collected at every visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(33) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(33) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical cetirizine</intervention_name>
    <description>Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Cetirizine 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>96% ethanol that will be applied once daily.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>96% ethanol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical minoxidil</intervention_name>
    <description>Topical Minoxidil 5% that will be applied once daily.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Minoxidil 5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females with androgenetic alopecia of age 20-50 years.&#xD;
&#xD;
          2. Patients experiencing active hair loss within the last 12 months.&#xD;
&#xD;
          3. Sinclair scale 2, 3 and 4.&#xD;
&#xD;
          4. Patients willing to continue their current regimen of vitamins and nutritional&#xD;
             supplements and not start any new vitamins or nutritional supplements for the duration&#xD;
             of the study.&#xD;
&#xD;
          5. Patients willing to use a mild non-medicated shampoo and conditioner for the duration&#xD;
             of the study.&#xD;
&#xD;
          6. Patients who did not receive topical or systemic treatment for androgenetic alopecia&#xD;
             or prostaglandins in the last 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients with a chronic dermatological condition (eczema, psoriasis, infection,&#xD;
             etc) of the scalp other than FPHL.&#xD;
&#xD;
             2. Subjects who had hair transplants, scalp reduction, current hair weave or tattooing&#xD;
             in the target area, which makes it difficult to perform hair count assessment.&#xD;
&#xD;
             3. Subjects who received radiation therapy to the scalp, or has had chemotherapy in&#xD;
             the past year.&#xD;
&#xD;
             4. Subjects who have a known underlying medical problem that could influence hair&#xD;
             growth such as HIV infection, connective tissue disease, a thyroid condition,&#xD;
             inflammatory bowel disease or other medical conditions, at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
             5. Subjects with clinical diagnosis of alopecia areata or other non-AGA forms of&#xD;
             alopecia.&#xD;
&#xD;
             6. Pregnant or lactating females or planning to become pregnant for the duration of&#xD;
             the study.&#xD;
&#xD;
             7. Patients with severe cardiovascular disease, uncontrolled or untreated&#xD;
             hypertension, arrythmia or clinically relevant hypotension.&#xD;
&#xD;
             8. Subjects with hair loss for greater than 5 years, as medical therapy is unlikely to&#xD;
             have much effect at restoring hair follicles inactive for that long of a period.&#xD;
&#xD;
             9. The subject has known hypersensitivity or previous allergic reaction to any of the&#xD;
             active or inactive components of the test articles.&#xD;
&#xD;
             10. Patients using any medications that potentially cause drug-induced hair loss&#xD;
             (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone,&#xD;
             testosterone, divalproex sodium) within the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females with androgenetic alopecia of age 20-50.</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maggie Abbassi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Pharmacy, Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanan Nada, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samar Farid, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Pharmacy, Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Al-Kasr Al-Ainy outpatient dermatology clinic</name>
      <address>
        <city>Cairo</city>
        <state>ِAl-Kasr Al-Ainy</state>
        <zip>11559</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol. 1992 Sep;127(3):239-46. doi: 10.1111/j.1365-2133.1992.tb00121.x.</citation>
    <PMID>1390168</PMID>
  </reference>
  <reference>
    <citation>Guo H, Gao WV, Endo H, McElwee KJ. Experimental and early investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs. 2017 Aug;26(8):917-932. doi: 10.1080/13543784.2017.1353598. Epub 2017 Jul 12.</citation>
    <PMID>28689433</PMID>
  </reference>
  <reference>
    <citation>Rossi A, Campo D, Fortuna MC, Garelli V, Pranteda G, De Vita G, Sorriso-Valvo L, Di Nunno D, Carlesimo M. A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatolog Treat. 2018 Mar;29(2):149-151. doi: 10.1080/09546634.2017.1341610. Epub 2017 Jun 29.</citation>
    <PMID>28604133</PMID>
  </reference>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>February 7, 2023</last_update_submitted>
  <last_update_submitted_qc>February 7, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Samar Farghali Farid</investigator_full_name>
    <investigator_title>Head and professor of clinical pharmacy department</investigator_title>
  </responsible_party>
  <keyword>cetirizine</keyword>
  <keyword>minoxidil</keyword>
  <keyword>androgenetic alopecia (AGA)</keyword>
  <keyword>Female pattern hair loss (FPHL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Minoxidil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04481412
org study id: Cetirizine in alopecia
nct id: NCT04481412
lead sponsor: 
is fda regulated drug: No
is fda regulated device: No
Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist,
      widely used in daily practice. A study showed that cetirizine causes a significant reduction
      in both the inflammatory cell infiltrate and PGD2 production. A pilot study on topical
      cetirizine showed that cetirizine increased total hair density, terminal hair density and
      diameter. Also, its lower potential side effects if compared with other drugs commonly used
      for AGA, as minoxidil, can promote a wider use and better compliance of cetirizine in the
      future for the treatment of AGA. Combinations of therapies are likely to be more efficacious
      than single treatments.

      Treatments to clinically improve scalp hair density and reduce mid-pattern thinning leading
      to improved scalp coverage are highly important for the affected women. On the basis of the
      above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA
      treatment, the aim of this study is to evaluate the efficacy and tolerability of topical
      cetirizine in female patients with AGA.
Androgenetic alopecia (AGA) is the most common form of alopecia in men and women. It is a
      hereditary, androgen-dependent, progressive thinning of scalp hair that follows a defined
      pattern. The disease mechanism is still relatively poorly understood, but involves a strong
      genetic contribution as well as some environmental input. AGA manifests as a noticeable
      reduction of scalp hair coverage, shorter miniaturized telogen vellus hair follicles, and
      significantly slower rates of hair growth. Approximately 6% to 38% of healthy women
      experience some degree of frontal and frontoparietal hair loss. AGA may have significant
      impact on quality of life in female patients. When female AGA is associated with high levels
      of androgens, systemic antiandrogenic therapy may be needed. However, treating it with oral
      antiandrogens is usually ineffective suggesting that most female AGA cases are not systemic
      androgen dependent and topical treatment may be more appropriate.

      Currently, the only clinically validated and licensed medication approved for increasing hair
      density in women with AGA is 2 % minoxidil topical solution, and up to 5% minoxidil in
      several countries. The collective effects of minoxidil lead to increased cutaneous blood
      flow, prolongation of the anagen growth phase, and increase in the size of smaller hair
      follicles. However, it produces moderate results, and must continue to be used to have a
      continued benefit, and may produce adverse side effects. The use of higher concentrations of
      minoxidil in women is supported by results from an early study suggesting that concentrations
      higher than 2% could improve efficacy without increasing the rates of adverse events when
      applying not more than 60 mg of minoxidil per day.

      Based on the hypertrichosis observed in patients treated with analogues of prostaglandin F2a
      (PGF2a) (i.e. latanoprost used for glaucoma), it was supposed that prostaglandins would have
      an important role in hair growth. Their action is variable depending on the class they belong
      to: prostaglandin E(PGE) and PGF2a play a generally positive role on the hair growth, while
      PGD2 has an inhibitory role on the hair growth. Elevated levels of prostaglandin D2 synthase
      (PGDS) were found at the messenger ribonucleic acid (mRNA) and protein levels in bald scalp
      versus haired scalp of men with AGA; as well as the enzymatic product of PGDS, (PGD2), is
      generally elevated in bald human scalp tissue.

      Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist,
      widely used in daily practice. A study showed that cetirizine causes a significant reduction
      in both the inflammatory cell infiltrate and PGD2 production. However, these effects
      apparently are not related to its anti-H1 activity. A pilot study on topical cetirizine
      showed that cetirizine increased total hair density, terminal hair density and diameter.
      Also, its lower potential side effects if compared with other drugs commonly used for AGA, as
      minoxidil (which often cause of hypertrichosis, contact allergic dermatitis, headache and
      hypotension), can promote a wider use and better compliance of cetirizine in the future for
      the treatment of AGA. Combinations of therapies are likely to be more efficacious than single
      treatments.

      Treatments to clinically improve scalp hair density and reduce mid-pattern thinning leading
      to improved scalp coverage are highly important for the affected women. On the basis of the
      above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA
      treatment, the aim of this study is to evaluate the efficacy and tolerability of topical
      cetirizine in female patients with AGA.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Triple (Participant, Care Provider, Outcomes Assessor)
measure: The change from baseline in number of terminal hairs and vellus hair
time frame: baseline, 12, 24 weeks
description: Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in number of terminal hairs, growing hair and vellus hair.
measure: The change from baseline in hair shaft thickness
time frame: baseline, 12, 24 weeks
description: Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in hair shaft thickness.
measure: The change from baseline in terminal and vellus hair density
time frame: baseline, 12, 24 weeks
description: Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in number of follicular openings.
measure: The change in patient self-assessment from baseline
time frame: baseline, 6, 12, 18, 24 weeks
description: Patient self-assessment of hair growth will be determined by means of a set of predetermined 5 questions in Arabic, each of which asks the patient about a specific aspect of their hair compared with the start of the study.
measure: The change in hair growth from baseline using global photographic assessment
time frame: baseline, 12, 24 weeks
description: Standardized photographs of the scalp will be taken.
An expert panel of 3 blinded dermatologists will evaluate hair growth or loss from baseline by comparing baseline with follow-up photographs of each subject by means of a 7-point scale to answer the following question: "How would you subjectively rate the patient's hair growth at this time point compared to baseline?". The scale ranges from-3 ( greatly decreased) to +3 (greatly increased). Assessments will be made at the 12th and 24th week by comparing the global photographs taken at baseline with those taken at each visit.
Investigator assessment: Same as the expert panel assessment.
measure: Number of patients with adverse effects
time frame: 6, 12, 18, 24 weeks
description: Reports of adverse effects or local intolerance, if any, will be collected at every visit.
arm group label: Study group
arm group type: Experimental
description: (33) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.
arm group label: Control group
arm group type: Active Comparator
description: (33) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.
intervention type: Drug
intervention name: Topical cetirizine
description: Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.
arm group label: Study group
other name: Cetirizine 1%
intervention type: Drug
intervention name: Placebo
description: 96% ethanol that will be applied once daily.
arm group label: Control group
other name: 96% ethanol
intervention type: Drug
intervention name: Topical minoxidil
description: Topical Minoxidil 5% that will be applied once daily.
arm group label: Control group
arm group label: Study group
other name: Minoxidil 5%
criteria: 
gender: Female
gender based: Yes
gender description: Females with androgenetic alopecia of age 20-50.
minimum age: 20 Years
maximum age: 50 Years
healthy volunteers: No
last name: Maggie Abbassi, PhD
role: Study Chair
affiliation: Faculty of Pharmacy, Cairo University
last name: Hanan Nada, PhD
role: Study Chair
affiliation: Cairo University
last name: Samar Farid, PhD
role: Principal Investigator
affiliation: Faculty of Pharmacy, Cairo University
facility: 
country: Egypt
citation: Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol. 1992 Sep;127(3):239-46. doi: 10.1111/j.1365-2133.1992.tb00121.x.
PMID: 1390168
citation: Guo H, Gao WV, Endo H, McElwee KJ. Experimental and early investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs. 2017 Aug;26(8):917-932. doi: 10.1080/13543784.2017.1353598. Epub 2017 Jul 12.
PMID: 28689433
citation: Rossi A, Campo D, Fortuna MC, Garelli V, Pranteda G, De Vita G, Sorriso-Valvo L, Di Nunno D, Carlesimo M. A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatolog Treat. 2018 Mar;29(2):149-151. doi: 10.1080/09546634.2017.1341610. Epub 2017 Jun 29.
PMID: 28604133
responsible party type: Principal Investigator
investigator affiliation: Cairo University
investigator full name: Samar Farghali Farid
investigator title: Head and professor of clinical pharmacy department
mesh term: Alopecia
mesh term: Alopecia Areata
mesh term: Cetirizine
mesh term: Ethanol
mesh term: Minoxidil
sharing ipd: No